LAUSR

Although we agree with Chaudhuri and colleagues that the prevalence of dyskinesia is less than in the past, we again emphasize that this may come at the expense of undertreating our patients. A highly effective, well-tolerated anti-dyskinesia therapy would afford us the opportunity to use levodopa more liberally to improve patients’ motor function and quality of life. We can and should pursue therapeutic advances in multiple areas of unmet need, including disease modification, nonmotor symptoms, and motor impairment, including dyskinesia. Our patients will benefit from successes achieved.